Back to search results

Observational Study of Tirbanibulin for Actinic Keratosis on the Face

This observational study, called CLEAR, is looking at how well tirbanibulin ointment 1% works for adults with actinic keratosis (AK) on their face. AKs are rough, scaly patches on the skin that develop from years of sun exposure. The study wants to understand how tirbanibulin improves the overall appearance of your skin, how your skin looks, and its texture over 57 days. You would be eligible if you are at least 18 years old, have 4-12 visible AK lesions on your face, and are already considered a candidate for tirbanibulin treatment. The study is currently enrolling 30 participants.

Study design
This is an observational study with 30 participants. It aims to understand the effects of tirbanibulin in a real-world setting.
What's involved
Participants already taking tirbanibulin will answer online survey questions at the beginning of the study and again at Day 57.
Compensation
Not stated in the trial record.
Follow-up
Participants are observed for 57 days after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07657988

Outcomes Associated With Tirbanibulin for Large Field Application on the Face in the U.S (CLEAR)

Recruiting
Not specifiedAges 18+Observational
Avant Health LLC
~30 participants
Updated 2026-06-18 on ClinicalTrials.gov
What's tested:Tirbanibulin

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Subject and clinician rating of current 'overall appearance of the skin' in the original AK treated area
Measured over At end of study observation period, at day 57
+1 more outcome measured

Conditions

Actinic Keratosis (AK)

Explore related trials

Actinic Keratosis

NCT07657988

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Ablon Skin Institute and Research Center

    Manhattan Beach, Californiastudy coordinator listed

    Recruiting

  • Dermatology & Laser Center of Charleston

    Charleston, South Carolinastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Siva Narayanan, PhD, MPhil, MHS, MSc · STUDY_CHAIR · Avant Health LLC
  • Todd Schlesinger, MD · PRINCIPAL_INVESTIGATOR · Avant Health LLC

Who to contact

Siva Narayanan, PhD, MPhil, MHS, MSc
[email protected]
301-799-AVANT
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosed with AK on the face.
Has clinically typical, visible, and discrete 4-12 AK lesions on the face.
Considered as a potential candidate for tirbanibulin (Klisyri®) treatment to manage their AK lesions on the face.
Male or female, aged 18 years and above at the time of initiation of treatment with tirbanibulin.
Willing to avoid excessive sun or UV exposure, and/or use relevant sunscreen protection and protective clothing during the study duration.
Able to read and write in English.
Provide consent to participate in the study.
Willing to comply with all study procedures (including photography tasks) and be available for the duration of the study.

Exclusion

Patients with any dermatological condition of the face that could interfere with clinical evaluations.
Hypertrophic AK lesions, open wounds, or suspected skin cancers within proximity of the treatment area.
Anticipated need for in-patient hospitalization or in-patient surgery within the next 2 months.
Patients unable to comply with the requirements of the study or patients who, in the opinion of the study physician should not participate in the study.
Patients for whom medical chart is inaccessible to physicians to complete baseline data collection.

What this trial measures

  • Subject and clinician rating of current 'overall appearance of the skin' in the original AK treated areaAt end of study observation period, at day 57

    The overall appearance of the skin in the original AK treated area (in comparison to baseline) is rated on a 5-point Likert scale of much worse, somewhat worse, no change, somewhat improved, much improved.

  • Subject and clinician rating of their satisfaction with the ability of tirbanibulin treatment to 'improve how skin looks' and 'improve skin texture' respectively, in the original AK treated areaAt the end of study observation period, at day 57

    Satisfaction is rated on a 7-point Likert scale of extremely satisfied, very satisfied, dissatisfied, somewhat satisfied, satisfied, very satisfied, extremely satisfied.